Howard E (Ted) Greene Jr

Howard E. (Ted) Greene, Jr. is an accomplished entrepreneur and investor in the biotechnology industry. During a business career spanning over four decades, Mr. Greene has been successful in various aspects of early stage medical technology companies. Both as an inventor and entrepreneur, and as a venture capitalist, he has been involved in starting, funding, and/or managing numerous technology-driven enterprises, many of which have gone public.

Prior to his retirement from full time employment in 1998, Mr. Greene was CEO and Chairman of Amylin Pharmaceuticals, Inc., a company he co-founded in 1987 to pioneer research of the hormone amylin, which was discovered in the same year. The company went on to market two first-in-class diabetes drugs: an amylin analog, SYMLIN, which can improve glucose control for diabetic patients who must take insulin; and a GLP-1 mimic, BYETTA or BYDUREON, which can improve glucose control and cause weight loss in patients who are failing to achieve satisfactory results with oral diabetes drugs or insulin. Amylin’s product pipeline included drug candidates for treating metabolic disorders. Mr. Greene is an inventor on several patents directed to using the hormone amylin in diabetes therapy. Amylin was acquired by Bristol-Myers Squibb in 2012.

Before starting Amylin, Mr. Greene co-founded Biovest Partners, a venture capital firm that in two years provided seed capital and management leadership for six medical technology start-up companies, including Amylin, and that returned about ten-fold its limited partners’ capital in less than five years. All six companies were taken public: Amylin now part of AstraZeneca; Pyxis Corporation, now part of BD; Neurex Corporation, purchased by Elan; Cytel/Epimmune merged with IDM Pharma, Biosite Incorporated, now part of Abbott and Quidel, and Vical Inc., now merged into Brickell.

Prior to Biovest, Mr. Greene was Chief Executive Officer of Hybritech Incorporated, essentially from inception until its acquisition by Eli Lilly and Company in 1986. At Hybritech he was co-inventor of its principal product line, a monoclonal antibody assay system that was a new technology for testing clinical proteins, including the PSA screening test for prostate cancer. This type of assay is now the clinical standard for measuring proteins in blood. Mr. Greene led Hybritech to become an 800-employee company that pioneered the first monoclonal antibody diagnostic and therapeutic technologies, and whose employees seeded the biotech industry in San Diego.

Before Hybritech, Mr. Greene was an executive with Baxter International for five years, and prior to that he was a consultant with McKinsey & Company for seven years. He is presently a director of and investor in three early stage startups in the biotech and internet fields: Bilarm Healthcare, Bambino Technologies, and SafetySkills.com. Mr. Greene holds a BA in physics from Amherst College and an MBA in decisions under uncertainty from Harvard University. His primary interests these days are his thirteen grandchildren and boating.